Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 22 Mar 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Mar 2019 as reported by ClinicalTrials.gov.
- 22 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 26 Oct 2015 New trial record